Fennec Pharmaceuticals Inc. (FENC): Cash & Equivalents
$36.79M
As of 2025-12-31
$41.25M
As of 2026-06-30
+15.7%
3-year compound annual growth
+3.9%
5-year compound annual growth
+44.3%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $36.79M | +38.1% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $26.63M | +100.7% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $13.27M | -44.2% | 2025-03-26, Balance as of period end |
| 2022-12-31 | $23.77M | +12.7% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $21.10M | -30.5% | 2023-03-29, Balance as of period end |
| 2020-12-31 | $30.34M | +122.3% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $13.65M | -40.1% | 2021-03-30, Balance as of period end |
| 2018-12-31 | $22.78M | -19.4% | 2020-02-14, Balance as of period end |
| 2017-12-31 | $28.26M | +619.8% | 2019-03-15, Balance as of period end |
| 2016-12-31 | $3.93M | +316.8% | 2018-03-28, Balance as of period end |
| 2015-12-31 | $942.0K | -59.2% | 2017-03-29, Balance as of period end |
| 2014-12-31 | $2.31M | +38.7% | 2016-03-28, Balance as of period end |
| 2013-12-31 | $1.66M | -27.8% | 2015-03-31, Balance as of period end |
| 2012-12-31 | $2.30M | -56.5% | 2014-03-31, Balance as of period end |
| 2011-12-31 | $5.30M | -10.9% | 2014-03-31, Balance as of period end |
| 2010-12-31 | $5.95M | +768.2% | 2013-04-01, Balance as of period end |
| 2009-12-31 | $685.0K | n/a | 2012-03-27, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $36.79M | +38.1% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $146.65M | +11.5% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $65.30M | -8.5% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $20.95M | -50.0% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $357.01M | +196.9% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $14.68M | -25.7% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $226.69M | +226.9% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $74.60M | +34.4% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $217.05M | +289.7% |
Compare FENC, EDIT, VYGR, SGMOQ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗